Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Minerva Neurosciences Inc (NERV)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.57+9.36%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for NERV yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain $200 million equity offering program | It has a $200 million equity program to fund operations. | Intact | Equity program is reduced or unavailable before 2026-Q1 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making clinical-stage company, not an established earnings compounder. The long-term thesis is in a watch state: the Phase 3 program is progressing, but recent financial performance is weak and near-term execution risk is elevated.
The evidence snapshot provides no valuation or market-expectations data, so whether NERV looks cheap or expensive versus peers cannot be assessed. Recent performance has lagged its industry cohort, and the thesis has not freshly broken, but the evidence does not show what expectations are already reflected.
Near term, consecutive earnings misses leave an elevated risk of another miss, while cash has declined and liabilities have increased. Management says the Phase 3 confirmatory trial for roluperidone remains on track, with topline efficacy data expected in the second half of 2027; R&D spending rose as trial investment increased. Financing and leadership transitions remain areas to monitor.
The multi-year view hinges on completing the Phase 3 trial and producing the expected efficacy data, alongside the company’s ability to manage its capital needs. A guidance cut or further earnings weakness would add pressure, while continued strength among healthcare sector bellwethers could support the sector backdrop. The jobs trend is another risk factor in the evidence, though its specific effect on NERV is uncertain.
Over the next 1 to 3 years, NERV remains a high-risk, evidence-dependent thesis with a clinical milestone ahead and weak near-term fundamentals. Progress on the trial and capital management are central to the read. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company aims to control losses while advancing its drug. |
| Broken |
| Operating loss exceeds negative $16.7 million in 2026-Q1 |
Operating income: $-10.642M FY2026-Q2; GAAP. Published target: Operating loss no worse than negative $16.7 million in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 7, 2026-10,642,159 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Complete Phase 3 trial enrolling 380 patients | Minerva is running a key Phase 3 trial with 380 patients. | Intact | Trial enrollment falls short of 380 patients by 2026-Q1 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “We remain focused on execution and on track for topline efficacy data in the second half of 2027.”” “• The Company screened the first patient in March 2026, marking an important operational milestone for the program.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.80 → $-0.68 · observed estimates
$0.06B → $0.06B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-07-25 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-07-26 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-07-27 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-07-28 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-07-29 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-07-30 | $-0.80 | $0 | 2 / 3 |
| 2026-07-31 | $-0.80 | $0 | 2 / 3 |
| 2026-08-01 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-02 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-03 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-04 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-05 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-06 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-07 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-08 | $-0.80 | $0 | 2 / 3 |
| 2026-08-09 | $-0.80 | $0 | 2 / 3 |
| 2026-08-10 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-12 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-13 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-14 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-15 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-16 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-17 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-18 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-19 | $-0.80 | $56,492,000 | 1 / 3 |
| 2026-08-20 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-08-21 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-08-22 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-08-23 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-08-24 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-08-25 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-08-26 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-08-27 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-08-28 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-08-29 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-08-30 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-08-31 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-01 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-02 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-03 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-04 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-05 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-06 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-07 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-08 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-09 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-10 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-11 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-12 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-13 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-14 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-15 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-16 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-17 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-18 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-19 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-20 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-21 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-22 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-23 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-24 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-25 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-26 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-27 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-28 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-29 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-09-30 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-01 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-02 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-03 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-04 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-05 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-06 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-07 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-08 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-09 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-10 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-11 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-12 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-13 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-14 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-15 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-16 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-17 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-18 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-19 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-20 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-21 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-22 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-23 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-24 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-25 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-26 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-27 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-28 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-29 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-30 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-10-31 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-11-01 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-11-02 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-11-03 | $-0.68 | $56,492,000 | 1 / 3 |
| 2026-11-04 | $-0.68 | $56,492,000 | 1 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.